High burden of tuberculosis infection and disease among people receiving medication-assisted treatment for substance use disorder in Tanzania.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
12
2020
accepted:
29
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
2
10
2021
Statut:
epublish
Résumé
To determine the prevalence of tuberculosis (TB) disease and infection as well as incident TB disease among people who use drugs (PWUD) attending Medication Assisted Treatment (MAT) clinics in Dar-es-Salaam, Tanzania. In this prospective cohort study, a total of 901 consenting participants were enrolled from November 2016 to February 2017 and a structured questionnaire administered to them through the open data kit application on android tablets. Twenty-two months later, we revisited the MAT clinics and reviewed 823 of the 901 enrolled participant's medical records in search for documentation on TB disease diagnosis and treatment. Medical records reviewed included those of participants whom at enrolment were asymptomatic, not on TB disease treatment, not on TB preventive therapy and those who had a documented tuberculin skin test (TST) result. Of the 823 medical records reviewed 22 months after enrolment, 42 had documentation of being diagnosed with TB disease and initiated on TB treatment. This is equivalent to a TB disease incidence rate of 2,925.2 patients per 100,000 person years with a total follow up time of 1,440 person-years. At enrolment the prevalence of TB disease and TB infection was 2.6% and 54% respectively and the HIV prevalence was 44% and 16% among females and males respectively. PWUD attending MAT clinics bear an extremely high burden of TB and HIV and are known to have driven TB epidemics in a number of countries. Our reported TB disease incidence is 12 times that of the general Tanzanian incidence of 237 per 100,000 further emphasizing that this group should be prioritized for TB screening, testing and treatment. Gender specific approaches should also be developed as female PWUDs are markedly more affected with HIV and TB disease than male PWUDs.
Identifiants
pubmed: 33914753
doi: 10.1371/journal.pone.0250038
pii: PONE-D-20-39612
pmc: PMC8084249
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250038Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur Respir J. 2016 Jul;48(1):269-71
pubmed: 27103393
J Bras Pneumol. 2018 Apr;44(2):145-152
pubmed: 29791552
PLoS Med. 2010 Dec 21;7(12):e1000381
pubmed: 21203587
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9557-62
pubmed: 22645356
Clin Infect Dis. 2012 Mar;54(6):784-91
pubmed: 22267721
AIDS. 2015 Jul 17;29(11):1391-9
pubmed: 26091295
AIDS Care. 2005 Jun;17 Suppl 1:S65-76
pubmed: 16096119
Ther Clin Risk Manag. 2015 Oct 06;11:1539-44
pubmed: 26504395
JAMA. 2005 Jun 8;293(22):2762-6
pubmed: 15941806
Ann N Y Acad Sci. 1975 Apr 25;252:353-64
pubmed: 1056734
Lancet Infect Dis. 2012 Jan;12(1):45-55
pubmed: 21846592
Microbiol Spectr. 2017 Jan;5(1):
pubmed: 28185619
Int J Tuberc Lung Dis. 2003 Sep;7(9):860-5
pubmed: 12971670
Lancet. 2010 May 29;375(9729):1852-4
pubmed: 20488519
AIDS Behav. 2007 Jan;11(1):137-44
pubmed: 17004117
Curr Opin HIV AIDS. 2012 Jul;7(4):345-53
pubmed: 22678489
Ir Med J. 2010 Oct;103(9):278-80
pubmed: 21186753
Int J Tuberc Lung Dis. 2014 Jul;18(7):793-8
pubmed: 24902554
Int J Tuberc Lung Dis. 2003 Dec;7(12 Suppl 3):S486-93
pubmed: 14677842
Clin Infect Dis. 2009 Jan 1;48(1):72-82
pubmed: 19046064
Int J Drug Policy. 2014 Jan;25(1):22-5
pubmed: 24210295
Lancet Infect Dis. 2019 Mar;19(3):e96-e108
pubmed: 30322790
Int J Tuberc Lung Dis. 2004 Apr;8(4):392-402
pubmed: 15141729
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
Arch Fam Med. 1995 Jun;4(6):541-6
pubmed: 7773431
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000171
pubmed: 20091503
Biochem Pharmacol. 2003 Jun 1;65(11):1761-6
pubmed: 12781327
Int J Drug Policy. 2013 Jan;24(1):78-81
pubmed: 23036650
J Infect. 2017 Sep;75(3):191-197
pubmed: 28676410
Eur Respir J. 2014 Feb;43(2):630-2
pubmed: 24072215
Clin Microbiol Rev. 2003 Apr;16(2):209-19
pubmed: 12692094
Am J Respir Crit Care Med. 1998 Aug;158(2):484-8
pubmed: 9700125
Bull World Health Organ. 2013 Feb 1;91(2):154-6
pubmed: 23554532
Lancet Infect Dis. 2016 Feb;16(2):227-38
pubmed: 26867464
Thorax. 2005 Jul;60(7):555-7
pubmed: 15994262
J Am Med Inform Assoc. 2016 Sep;23(5):916-23
pubmed: 26911813
Clin Infect Dis. 2020 Sep 16;:
pubmed: 32936877
PLoS One. 2013 Jun 25;8(6):e67062
pubmed: 23825620
Clin Infect Dis. 2005 May 15;40(10):1500-7
pubmed: 15844073
Int J Tuberc Lung Dis. 2003 Mar;7(3):271-7
pubmed: 12661843